Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Follow-on discounts

Follow-on discounts

Company Proposed Filing date shares (MM) Benchmark (price on day of filing) Date completed Offer price Final shares (MM) Amount raised (MM) % above or below benchmark
Telios TLIO 11-Dec-92 4.0 $8.250 26-Jan-93 $6.000 4.0 $24.0 -38%
Calgene CGNE 14-Dec 2.0 $15.750 26-Jan $14.750

Read the full 465 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers